Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21


Motivational Context Modulates Prediction Error Response in Schizophrenia.

Reinen JM, Van Snellenberg JX, Horga G, Abi-Dargham A, Daw ND, Shohamy D.

Schizophr Bull. 2016 Nov;42(6):1467-1475. doi: 10.1093/schbul/sbw045. Epub 2016 Apr 22.


Application of a cocktail approach to screen cytochrome P450 BM3 libraries for metabolic activity and diversity.

Reinen J, Postma G, Tump C, Bloemberg T, Engel J, Vermeulen NP, Commandeur JN, Honing M.

Anal Bioanal Chem. 2016 Feb;408(5):1425-43. doi: 10.1007/s00216-015-9241-x. Epub 2016 Jan 11.


Application of a Continuous-Flow Bioassay to Investigate the Organic Solvent Tolerability of Cytochrome P450 BM3 Mutants.

Reinen J, van Hemert D, Vermeulen NP, Commandeur JN.

J Biomol Screen. 2015 Dec;20(10):1246-55. doi: 10.1177/1087057115607183. Epub 2015 Sep 22.


Characterization of human cytochrome P450s involved in the bioactivation of tri-ortho-cresyl phosphate (ToCP).

Reinen J, Nematollahi L, Fidder A, Vermeulen NP, Noort D, Commandeur JN.

Chem Res Toxicol. 2015 Apr 20;28(4):711-21. doi: 10.1021/tx500490v. Epub 2015 Mar 2.


Antipsychotic dose modulates behavioral and neural responses to feedback during reinforcement learning in schizophrenia.

Insel C, Reinen J, Weber J, Wager TD, Jarskog LF, Shohamy D, Smith EE.

Cogn Affect Behav Neurosci. 2014 Mar;14(1):189-201. doi: 10.3758/s13415-014-0261-3.


Patients with schizophrenia are impaired when learning in the context of pursuing rewards.

Reinen J, Smith EE, Insel C, Kribs R, Shohamy D, Wager TD, Jarskog LF.

Schizophr Res. 2014 Jan;152(1):309-10. doi: 10.1016/j.schres.2013.11.012. Epub 2013 Dec 13. No abstract available.


Endocrine disrupting chemicals-Linking internal exposure to vitellogenin levels and ovotestis in Abramis brama from Dutch surface waters.

Reinen J, Suter MJ, Vögeli AC, Fernandez MF, Kiviranta H, Eggen RI, Vermeulen NP.

Environ Toxicol Pharmacol. 2010 Nov;30(3):209-23. doi: 10.1016/j.etap.2010.07.004. Epub 2010 Aug 3.


Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space.

Reinen J, van Leeuwen JS, Li Y, Sun L, Grootenhuis PD, Decker CJ, Saunders J, Vermeulen NP, Commandeur JN.

Drug Metab Dispos. 2011 Sep;39(9):1568-76. doi: 10.1124/dmd.111.039461. Epub 2011 Jun 14.


Application of a fluorescence-based continuous-flow bioassay to screen for diversity of cytochrome P450 BM3 mutant libraries.

Reinen J, Ferman S, Vottero E, Vermeulen NP, Commandeur JN.

J Biomol Screen. 2011 Feb;16(2):239-50. doi: 10.1177/1087057110394180.


Application of cytochrome P450 BM3 mutants as biocatalysts for the profiling of estrogen receptor binding metabolites of the mycotoxin zearalenone.

Reinen J, Kalma LL, Begheijn S, Heus F, Commandeur JN, Vermeulen NP.

Xenobiotica. 2011 Jan;41(1):59-70. doi: 10.3109/00498254.2010.525762. Epub 2010 Nov 18.


Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease.

Roberts KE, Kawut SM, Krowka MJ, Brown RS Jr, Trotter JF, Shah V, Peter I, Tighiouart H, Mitra N, Handorf E, Knowles JA, Zacks S, Fallon MB; Pulmonary Vascular Complications of Liver Disease Study Group.

Gastroenterology. 2010 Jul;139(1):130-9.e24. doi: 10.1053/j.gastro.2010.03.044. Epub 2010 Mar 24.


Health-related quality of life and survival in liver transplant candidates.

Tanikella R, Kawut SM, Brown RS Jr, Krowka MJ, Reinen J, Dinasarapu CR, Trotter JF, Roberts KE, Mohd MA, Arnett DK, Fallon MB.

Liver Transpl. 2010 Feb;16(2):238-45. doi: 10.1002/lt.21984.


Comparison of murine and human estrogen sulfotransferase inhibition in vitro and in silico--implications for differences in activity, subunit dimerization and substrate inhibition.

Stjernschantz E, Reinen J, Meinl W, George BJ, Glatt H, Vermeulen NP, Oostenbrink C.

Mol Cell Endocrinol. 2010 Apr 12;317(1-2):127-40. doi: 10.1016/j.mce.2009.12.001. Epub 2009 Dec 16.


Plasma levels of S100A4 in portopulmonary hypertension.

Peng T, Zamanian R, Krowka MJ, Benza RL, Roberts KE, Taichman DB, Rybak D, Trotter JF, Brown RS Jr, Fallon MB, Kawut SM; Pulmonary Vascular Complications of Liver Disease Study Group.

Biomarkers. 2009 May;14(3):156-60. doi: 10.1080/13547500902773896.


Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Kawut SM; Pulmonary Vascular Complications of Liver Disease Study Group.

Am J Respir Crit Care Med. 2009 May 1;179(9):835-42. doi: 10.1164/rccm.200809-1472OC. Epub 2009 Feb 12.


Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation.

Rybak D, Fallon MB, Krowka MJ, Brown RS Jr, Reinen J, Stadheim L, Faulk D, Nielsen C, Al-Naamani N, Roberts K, Zacks S, Perry T, Trotter J, Kawut SM; Pulmonary Vascular Complications of Liver Disease Study Group.

Liver Transpl. 2008 Sep;14(9):1357-65. doi: 10.1002/lt.21545.


Clinical risk factors for portopulmonary hypertension.

Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Brown RS Jr, Fallon MB; Pulmonary Vascular Complications of Liver Disease Study Group.

Hepatology. 2008 Jul;48(1):196-203. doi: 10.1002/hep.22275.


Reversed-phase liquid chromatography coupled on-line to estrogen receptor bioaffinity detection based on fluorescence polarization.

Reinen J, Kool J, Vermeulen NP.

Anal Bioanal Chem. 2008 Apr;390(8):1987-98. doi: 10.1007/s00216-008-1833-2. Epub 2008 Jan 31.


Development and validation of a fluorescence HPLC-based screening assay for inhibition of human estrogen sulfotransferase.

Reinen J, Vriese E, Glatt H, Vermeulen NP.

Anal Biochem. 2006 Oct 1;357(1):85-92. Epub 2006 Aug 1.


Supplemental Content

Loading ...
Support Center